ARTICLE | Product Development
With time at a premium, Alnylam’s siRNA strategy against COVID-19 could give it an advantage
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
May 6, 2020 1:32 AM UTC
Updated on May 6, 2020 at 1:57 AM UTC
Alnylam’s siRNA approach to treating COVID-19 will test the idea that the technology can compete with, and potentially upstage, small molecules and antibodies when it comes to development timelines.
At a minimum, the “front end” of the process, from concept to lead selection, is faster than traditional modalities, John Maraganore, CEO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), told BioCentury. “We went to a candidate in three months -- you can’t do that with a small molecule.” ...